A Review of Meningococcal Disease and Vaccination Recommendations for Travelers
Related Experiment Video
Updated: Feb 13, 2026

Expression and Purification of Virus-like Particles for Vaccination
Published on: June 2, 2016
Lidia C Serra1, Laura J York2, Amgad Gamil3
1Pfizer Vaccines, Medical Development, Scientific and Clinical Affairs, Collegeville, PA, USA. Lidia.Olveira@pfizer.com.
Abstract:
International travel has been steadily increasing since the middle of the twentieth century, including travel to regions with high levels of endemic meningococcal disease and areas with sporadic or sustained meningococcal outbreaks. Although invasive meningococcal disease (IMD) is relatively rare in travelers since the advent of quadrivalent meningococcal vaccines, it remains a serious concern because of its rapid progression, poor prognosis and outcomes, associated treatment delays, and the potential to precipitate outbreaks. Moreover, fatality occurs in up to 22% of those infected. This review will focus on IMD in travelers, with an emphasis on IMD epidemiology and the geographic regions of potential concern for international travelers. As vaccination is the best approach for preventing IMD among travelers, currently available meningococcal vaccines and corresponding country-specific national meningococcal vaccination recommendations, where available, will be summarized by age and type of vaccine recommended. The use of the quadrivalent meningococcal vaccines, specifically the tetanus toxoid conjugate vaccine (including MenACWY-TT; Nimenrix®), as a protective measure against IMD in travelers will be emphasized.
Funding:
Pfizer Inc.
Insights
International travel increases risk for invasive meningococcal disease (IMD). Quadrivalent vaccines, like MenACWY-TT, are crucial for preventing IMD in travelers, especially to high-risk regions.
Area of Science:
- Travel medicine
- Infectious disease epidemiology
- Vaccinology
Background:
- International travel has increased, exposing more individuals to regions with endemic or outbreak-prone meningococcal disease.
- Invasive meningococcal disease (IMD) poses risks including rapid progression, poor outcomes, and potential outbreaks, with up to 22% fatality.
- The funding for this review was provided by Pfizer Inc.
Purpose of the Study:
- To review the epidemiology of IMD in international travelers.
- To identify geographic regions of concern for travelers regarding IMD.
- To summarize available meningococcal vaccines and country-specific recommendations for travelers.
Main Methods:
- Literature review focusing on IMD epidemiology in travelers.
- Analysis of geographic risk factors for IMD.
- Summary of current meningococcal vaccine recommendations by country and age group.
Main Results:
- IMD remains a concern for travelers despite vaccine availability.
- Specific geographic regions present higher risks for travelers.
- Quadrivalent meningococcal vaccines, particularly MenACWY-TT, are emphasized for traveler protection.
Conclusions:
- Vaccination is the primary strategy for preventing IMD in international travelers.
- Travelers should be aware of IMD risks and consult country-specific vaccination guidelines.
- MenACWY-TT vaccine offers important protection against IMD for those traveling to high-risk areas.
More Related Videos
Related Concept Videos
Vaccinations
Travelling Waves
Water waves, sound waves, and seismic waves are some examples of mechanical waves. For water waves, the wave propagation medium is...
Traveling Waves: Lossless Lines
Review and Preview
Percentiles are a type of fractile that partition data into...
Review and Preview
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...

